Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Ilginatinib||NS-018||JAK2 Inhibitor - ATP competitive 15 SRC Inhibitor 31 YES Inhibitor 3||Ilginatinib (NS-018) inhibits JAK2, including JAK2 V617F, as well as SRC family members, including SRC, FYN, and YES, potentially leading to decreased cell proliferation (PMID: 24413068, PMID: 22829185, PMID: 29941953).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|JAK3 A572V||acute myeloid leukemia||predicted - resistant||Ilginatinib||Preclinical - Cell culture||Actionable||In a preclinical study, an acute myeloid leukemia cell line harboring JAK3 A572V was insensitive to treatment with Ilginatinib (NS-018) in culture (PMID: 22829185).||22829185|
|JAK2 V617F||hematologic cancer||sensitive||Ilginatinib||Preclinical||Actionable||In a preclinical study, cells expressing JAK2 V617F were sensitive to treatment with Ilginatinib (NS-018), demonstrating cell growth inhibition and increased apoptotic activity in culture and improved survival in transgenic mouse models (PMID: 22829185).||22829185|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04854096||Phase II||Ilginatinib||Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis||Recruiting||USA | ITA | GBR | DEU||4|